Vectibix

Vectibix Manufacturers

• Amgen Inc
  

  ×

  Vectibix | Amgen Inc

  

  ---

  2.1       Patient Selection

  Prior to initiation of treatment with Vectibix, assess RAS mutational status in colorectal tumors and confirm the absence of a RAS mutation.  Information on FDA-approved tests for the detection of KRAS mutations in patients with metastatic colorectal cancer is available at: http://www.fda.gov/CompanionDiagnostics.

  2.2       Recommended Dose

  The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. If the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes. Administer doses higher than 1000 mg over 90 minutes [see Dosage and Administration (2.4)].

  Appropriate medical resources for the treatment of severe infusion reactions should be available during Vectibix infusions [see Warnings and Precautions (5.4)].

  2.3       Dose Modifications

  Dose Modifications for Infusion Reactions [see Warnings and Precautions (5.4) and Adverse Reactions (6.1, 6.3)]

  Reduce infusion rate by 50% in patients experiencing a mild or moderate (grade 1 or 2) infusion reaction for the duration of that infusion.
  Terminate the infusion in patients experiencing severe infusion reactions.  Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.

  Dose Modifications for Dermatologic Toxicity [see Boxed Warning, Warnings and Precautions (5.1), and Adverse Reactions (6.1, 6.3)]

           • Upon first occurrence of a grade 3 (NCI-CTC/CTCAE) dermatologic reaction, withhold 1 to 2 doses of Vectibix. If the reaction improves to < grade 3, reinitiate Vectibix at the original dose.

           • Upon the second occurrence of a grade 3 (NCI-CTC/CTCAE) dermatologic reaction, withhold 1 to 2 doses of Vectibix. If the reaction improves to < grade 3, reinitiate Vectibix at 80% of the original dose.

           • Upon the third occurrence of a grade 3 (NCI-CTC/CTCAE) dermatologic reaction, withhold 1 to 2 doses of Vectibix. If the reaction improves to < grade 3, reinitiate Vectibix at 60% of the original dose.

           • Upon the fourth occurrence of a grade 3 (NCI-CTC/CTCAE) dermatologic reaction, permanently discontinue Vectibix.

  Permanently discontinue Vectibix following the occurrence of a grade 4 dermatologic reaction or for a grade 3 (NCI-CTC/CTCAE) dermatologic reaction that does not recover after withholding 1 or 2 doses.

  2.4       Preparation and Administration

  Do not administer Vectibix as an intravenous push or bolus.

  Preparation 
  Prepare the solution for infusion, using aseptic technique, as follows:

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.  Although Vectibix should be colorless, the solution may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates (which will be removed by filtration; see below).  Do not shake.  Do not administer Vectibix if discoloration is observed.
  Withdraw the necessary amount of Vectibix for a dose of 6 mg/kg.
  Dilute to a total volume of 100 mL with 0.9% sodium chloride injection, USP.  Doses higher than 1000 mg should be diluted to 150 mL with 0.9% sodium chloride injection, USP.  Do not exceed a final concentration of 10 mg/mL.
  Mix diluted solution by gentle inversion.  Do not shake.

  Administration

  • Administer using a low-protein-binding 0.2 μm or 0.22 μm in-line filter.
  • Vectibix must be administered via infusion pump.
        ◦ Flush line before and after Vectibix administration with 0.9% sodium chloride injection, USP, to avoid mixing with other drug products or intravenous solutions. Do not mix Vectibix with, or administer as an infusion with, other medicinal products. Do not add other medications to solutions containing panitumumab.

        ◦ Infuse doses of 1000 mg or lower over 60 minutes through a peripheral intravenous line or indwelling intravenous catheter. If the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes. Administer doses higher than 1000 mg over 90 minutes.

  • Use the diluted infusion solution of Vectibix within 6 hours of preparation if stored at room temperature, or within 24 hours of dilution if stored at 2° to 8°C (36º to 46ºF). DO NOT FREEZE.
  • Discard any unused portion remaining in the vial.

  Close
  No Recall

  More Info